Please login to the form below

Not currently logged in
Email:
Password:

Novartis’ Dr Esteban Pombo-Villar joins Oxford BioTherapeutics

Will head the UK biotech's new development operations in Switzerland

Dr Esteban Pombo Villar - Oxford BioTherapeuticsDr Esteban Pombo-Villar has left Novartis after 24 years to become chief operations officer of Oxford BioTherapeutics (OBT).

Dr Pombo-Villar will oversee the UK-based biotech's newly-created clinical development operations in Basel, Switzerland, as the company takes its therapeutic antibody and antibody drug conjugate (ADC) oncology programmes into clinical development.

During his time at Novartis Dr Pombo-Villar had several roles, the most recent of which was head of alliance management at the Novartis Institute for Biomedical Research (NIBR), where he focused creating and managing the company's collaborative efforts.

He initially joined Sandoz Neuroscience Research in 1988 to work on drug discovery projects and to investigate the potential of emerging technologies and remained at the company following Sandoz' merger with Ciba-Geigy in 1996 to form Novartis.

Dr Christian Rohlff, CEO of OBT, said: “I am very pleased to welcome Esteban to OBT and to officially open our new clinical operations site in Basel, Switzerland. Esteban's extensive executive leadership experience in the industry will bring considerable value to OBT as we advance our highly promising lead programmes into the clinic.”

4th May 2012

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
M&F Health

M&F Health is a full service communications agency, dedicated to the health and wellbeing sector. We are an independent amongst...

Latest intelligence

Is the pharma business model ready for precision medicine?
Precision medicine promises to revolutionise patient outcomes and reduce costs for industry but is pharma ready for it? Blue Latitude Health co-founder Head of Strategy Fred Bassett explores the challenges...
ABPI2018
The NHS and ABPI at 70: inching closer to the triple win
The NHS and UK pharma’s ABPI both turn 70 this year. After years of transactional relationships, there’s a will to work more closely - but friction on prices and value...
What pharma marketers can learn from behavioural science
Pharma behavioural science and traditional emotional marketing create a powerful mix of techniques that have impact on real lives....

Infographics